Diabetes drug Farxiga/Forxiga (dapagliflozin) looks set to become a new standard of care in the treatment of heart failure based on the results of the DAPA-HF Phase III trial presented at the European Society of Cardiology Congress in Paris, France on 1 September 2019. The product reduced the composite endpoint of cardiovascular death or worsening heart failure by 26% when given on top of standard of care and the benefits were seen in both diabetic and non-diabetic patients.
Farxiga Data Change Heart Failure Treatment Outlook
DAPA-HF data on AstraZeneca’s SGLT-2 inhibitor dapagliflozin as a treatment for heart failure in both diabetics and non-diabetics won spontaneous applause at ESC.
More from Cardiovascular
More from Therapy Areas
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.